TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Sanofi halts trial of COVID-19 drug after tests

News Desk (Agence France-Presse)
Paris, France
Tue, September 1, 2020 Published on Sep. 1, 2020 Published on 2020-09-01T14:02:23+07:00

Change text size

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Sanofi halts trial of COVID-19 drug after tests 			A photograph taken on March 27, 2020 shows a Sanofi's logo at the headquarters in Paris, during a strict lockdown in France aimed at curbing the spread of the COVID-19 infection, caused by the novel coronavirus.Sanofi said Tuesday that international Phase 3 clinical tests of its Kevzara drug for serious COVID-19 cases had proved inconclusive and it was halting the trial. (AFP/Franck Fife )

F

rench pharma giant Sanofi said Tuesday that international Phase 3 clinical tests of its Kevzara drug for serious COVID-19 cases had proved inconclusive and it was halting the trial.

The Phase 3 test -- normally the last before official approval for use -- "did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care," it said in a statement.

Sanofi said neither it nor its American partner in developing the drug, Regeneron, "envisage further clinical tests of Kevzara for the treatment of COVID-19."

Although Kevzara "did not give us the results we were hoping for, we are proud of the work done by our team," Sanofi global research head Dr. John Reed said in the statement.

Since the outbreak of the coronavirus pandemic late last year in China, it has claimed more than 800,000 lives and caused huge economic damage, sparking a global race to find a vaccine and effective treatments. 

Sanofi is one of many companies developing a vaccine but scientists are cautious in saying that at best, one may only be available by the end of this year for initial use.

 

 

 

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.

Share options

Quickly share this news with your network—keep everyone informed with just a single click!

Change text size options

Customize your reading experience by adjusting the text size to small, medium, or large—find what’s most comfortable for you.

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!

Continue in the app

Get the best experience—faster access, exclusive features, and a seamless way to stay updated.